STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIAF
  4. [8-K] bioAffinity Technologies, Inc. Reports Material Event

Nasdaq warns bioAffinity Technologies (BIAF) after shares trade below $1

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

bioAffinity Technologies, Inc. reports it received a Nasdaq Listing Qualifications Staff Determination on July 30, 2026 stating that the bid price of its common stock closed below $1.00 per share for 30 consecutive business days from June 16 through July 29, 2026, violating the Nasdaq Capital Market Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2).

Because the company effected a 1-for-30 reverse stock split on September 19, 2025, it is not eligible for the usual 180-calendar-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A). bioAffinity intends to submit an appeal to Nasdaq on August 6, 2026, which will stay delisting and suspension pending a Nasdaq Hearings Panel decision, but there is no assurance that any extension will be granted or that continued listing can be maintained.

Positive

  • None.

Negative

  • Nasdaq delisting notice after 30 days below $1.00 minimum bid.
  • No standard 180-day cure period because of prior 1-for-30 reverse split.
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities
The company received a delisting notice or transferred its listing to a different exchange.
Minimum Bid Price Requirement $1.00 per share Nasdaq Capital Market minimum bid price under Listing Rule 5550(a)(2)
Noncompliance duration 30 consecutive business days Bid price below $1.00 from June 16, 2026 through July 29, 2026
Noncompliance period June 16, 2026–July 29, 2026 Window during which bid price remained below $1.00 per share
Reverse stock split ratio 1-for-30 Reverse stock split effected on September 19, 2025
Reverse split date September 19, 2025 Effective date of the 1-for-30 reverse stock split
Appeal submission date August 6, 2026 Date the company intends to submit appeal to Nasdaq
Common stock par value $0.007 per share Par value of bioAffinity Technologies, Inc. common stock
Minimum Bid Price Requirement regulatory
"the Company is not in compliance with the minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
reverse stock split financial
"the Company effected a 1-for-30 reverse stock split on September 19, 2025"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Nasdaq Listing Rule 5550(a)(2) regulatory
"set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”)"
Nasdaq Listing Rule 5810(c)(3)(A)(iv) regulatory
"However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible"
Nasdaq Hearings Panel regulatory
"pending the decision of the Panel"
A Nasdaq hearings panel is a group of experts that reviews cases when a company's stock listing is at risk of being removed from the exchange. They evaluate whether the company has met certain standards and determine if it can keep trading on Nasdaq. This process matters to investors because it can affect a company's ability to raise money and maintain credibility in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →

FAQ

What triggered Nasdaq's delisting notice for bioAffinity Technologies (BIAF)?
Nasdaq staff notified bioAffinity after its common stock bid price stayed below $1.00 per share for 30 consecutive business days from June 16 through July 29, 2026, failing the Nasdaq Capital Market Minimum Bid Price Requirement under Listing Rule 5550(a)(2).

Why is bioAffinity Technologies (BIAF) not eligible for a 180-day compliance period?
The company effected a 1-for-30 reverse stock split on September 19, 2025. Under Nasdaq Listing Rule 5810(c)(3)(A)(iv), issuers that have completed a reverse split within the prior year are not eligible for the standard 180-calendar-day minimum bid price compliance period.

What action is bioAffinity Technologies (BIAF) taking in response to the Nasdaq notice?
bioAffinity intends to submit an appeal to Nasdaq on August 6, 2026. This appeal will stay any delisting and suspension action while a Nasdaq Hearings Panel reviews the matter and considers the company’s plans to regain compliance with the Minimum Bid Price Requirement.

What is the significance of the 1-for-30 reverse stock split for BIAF?
The 1-for-30 reverse stock split completed on September 19, 2025 temporarily boosted the share price but also affects compliance options. Because the split occurred within the past year, Nasdaq rules prevent bioAffinity from receiving the usual 180-day minimum bid price cure period.

Could bioAffinity Technologies (BIAF) lose its Nasdaq Capital Market listing?
The company states there is no assurance it can demonstrate compliance with the Minimum Bid Price Requirement or other rules before or after the hearing, nor that the Nasdaq Panel will grant additional time, so loss of its Nasdaq Capital Market listing is a disclosed risk.
false 0001712762 0001712762 2026-07-30 2026-07-30 0001712762 BIAF:CommonStockParValue0.007PerShareMember 2026-07-30 2026-07-30 0001712762 BIAF:WarrantsToPurchaseCommonStockMember 2026-07-30 2026-07-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 30, 2026

 

bioAffinity Technologies, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41463   46-5211056

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

 

3300 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

(Address of principal executive offices, including zip code)

 

(210) 698-5334

(Registrant’s telephone number, including area code)

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class   Trading Symbols   Name of each exchange on which registered

Common Stock, par value $0.007 per share

 

 

 

BIAF

 

  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

         
Warrants to purchase Common Stock   BIAFW  

The Nasdaq Stock Market LLC

(Nasdaq Capital Market)

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

On July 30, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”) received written notice (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Staff has determined that the bid price of the Company’s listed securities has closed at less than $1.00 per share over the previous thirty consecutive business days (from June 16, 2026 through July 29, 2026) and, as a result, the Company is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).

 

The Staff Determination further provided that normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Nasdaq Listing Rule 5810(c)(3)(A)(iv), the Company is not eligible for any compliance period specified in Nasdaq Listing Rule 5810(c)(3)(A) due to the fact that the Company has effected a reverse stock split over the prior one-year period. As previously disclosed in a Current Report on Form 8-K, the Company effected a 1-for-30 reverse stock split on September 19, 2025.

 

The Company intends to submit an appeal to Nasdaq on August 6, 2026, which will stay the delisting and suspension of the Company’s securities pending the decision of the Panel. At the hearing, the Company intends to present its views and its plans to regain compliance with the Minimum Bid Price Requirement. There can be no assurance that the Company will be able to evidence compliance with the Minimum Bid Price Requirement or any other applicable requirements for continued listing on The Nasdaq Capital Market prior to the hearing.

 

There can be no assurance that the Panel will grant the Company any extension period within which to regain compliance with the Minimum Bid Price Requirement, or if any such extension period is granted, that the Company will regain compliance with the Minimum Bid Price Requirement within such extension period, or that the Company will be successful in otherwise maintaining the listing of its securities on The Nasdaq Capital Market.

 

This report contains forward-looking statements, including, but not limited to, the timing of the hearing and the timing of the decision of the Panel. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied by such forward-looking statements. In particular, the hearing may be scheduled, and the Panel may issue a decision, more quickly than expected based on the typical time periods in published Nasdaq guidance, which shorter timeline(s) may be unfavorable for the Company and the continued listing of the Company’s common stock on The Nasdaq Capital Market. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report. The Company undertakes no obligation to update any forward-looking statement in this report, except as required by law.

 

-2-

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 31, 2026 BIOAFFINITY TECHNOLOGIES, INC.
   
  By: /s/ Maria Zannes
  Name: Maria Zannes
  Title: President and Chief Executive Officer

 

-3-

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Other Documents